Voyager Therapeutics Inc. (VYGR) Upgraded at Zacks Investment Research
Voyager Therapeutics Inc. (NASDAQ:VYGR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage presently has a $13.00 target price on the stock. Zacks Investment Research’s target price points to a potential upside of 15.35% from the stock’s current price.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Other equities analysts also recently issued reports about the company. Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Cowen and Company reiterated a “buy” rating on shares of Voyager Therapeutics in a research note on Wednesday, June 22nd. Finally, Stifel Nicolaus started coverage on Voyager Therapeutics in a research note on Thursday, July 14th. They issued a “buy” rating and a $33.00 price objective for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $26.80.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/voyager-therapeutics-inc-vygr-upgraded-at-zacks-investment-research.html
Voyager Therapeutics (NASDAQ:VYGR) traded down 3.18% during trading on Wednesday, hitting $11.27. 31,207 shares of the stock traded hands. The company’s market cap is $301.22 million. The company’s 50 day moving average price is $12.86 and its 200 day moving average price is $12.72. Voyager Therapeutics has a 12 month low of $8.12 and a 12 month high of $30.54.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.03. Voyager Therapeutics had a negative return on equity of 25.13% and a negative net margin of 150.47%. On average, equities research analysts anticipate that Voyager Therapeutics will post ($1.53) EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in VYGR. Vanguard Group Inc. boosted its position in shares of Voyager Therapeutics by 1,487.3% in the second quarter. Vanguard Group Inc. now owns 312,593 shares of the company’s stock valued at $3,436,000 after buying an additional 292,900 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Voyager Therapeutics by 171.3% in the second quarter. JPMorgan Chase & Co. now owns 288,425 shares of the company’s stock valued at $3,170,000 after buying an additional 182,125 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Voyager Therapeutics by 106.8% in the second quarter. BlackRock Fund Advisors now owns 302,971 shares of the company’s stock valued at $3,330,000 after buying an additional 156,443 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Voyager Therapeutics during the first quarter valued at $873,000. Finally, State Street Corp boosted its stake in Voyager Therapeutics by 147.1% in the second quarter. State Street Corp now owns 142,611 shares of the company’s stock valued at $1,565,000 after buying an additional 84,906 shares during the last quarter. Institutional investors and hedge funds own 39.66% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.